Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis

References

• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163.
   PubMed Web of Science ®Google Scholar
• Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893–903.
   PubMed Web of Science ®Google Scholar
• Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem 2004;93:173–187.
   PubMed Web of Science ®Google Scholar
• Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res 2010;16:3019–3027.
   PubMed Web of Science ®Google Scholar
• Wang X, Ren JH, Lin F, et al. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther 2010;10:632–643.
   PubMed Web of Science ®Google Scholar
• Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;135:842–843.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26:433–442.
   PubMed Web of Science ®Google Scholar
• Fei M, Lu M, Wang Y, et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol 2009;26:178–185.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96:1525–1530.
   PubMed Web of Science ®Google Scholar
• Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 2013;210:2793–2802.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Malsak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341–1348.
   PubMed Web of Science ®Google Scholar
• Li Y, Feng L, Li Y, et al. Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide. Leuk Lymphoma 2014;55:1366–1372.
   PubMed Web of Science ®Google Scholar
• Nayak S, Shen M, Bunaciu RP, et al. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma 2010;51: 1734–1747.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Yang S, Chen YR, et al. Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PLoS One 2014;9:e98925.
   PubMed Web of Science ®Google Scholar
• Oki T, Matsuzawa Y, Yoshimoto A, et al. New antitumor antibiotics aclacinomycins A and B. J Antibiot (Tokyo) 1975;28:830–834.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Hajji N, Mateos S, Pastor N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res 2005;583:26–35.
   PubMed Web of Science ®Google Scholar
• Utsuno K, Tsuboi M. Degree of DNA unwinding caused by the binding of aclacinomycin A. Chem Pharm Bull (Tokyo) 1997; 45:1551–1557.
   PubMed Web of Science ®Google Scholar
• Isoe T, Naito M, Shirai A, et al. Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim Biophys Acta 1992;1117:131–135.
   PubMed Web of Science ®Google Scholar
• Lee YL, Chen CW, Liu FH, et al. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. PLoS One 2013;8:e61939.
   PubMed Web of Science ®Google Scholar
• Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol 1986;26:491–509.
   PubMed Web of Science ®Google Scholar
• Ohmori K, Shirai M, Kiyosaki T, et al. Effect of aclacinomycin A on bone marrow. Jpn J Antibiot 1980;33:436–452.
   PubMedGoogle Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships:the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Wang R, Xia L, Gabrilove J, et al. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide -induced apoptosis in acute myeloid leukemia cells. Leukemia 2013;27:315–324.
   PubMed Web of Science ®Google Scholar
• Yedjou C, Tchounwou P, Jenkins J, et al. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010;3:28.
   PubMed Web of Science ®Google Scholar
• Gartenhaus RB, Prachand SN, Paniaqua M, et al. Arsenic trioxide cytotoxicity in steroid and chemotherapy resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002;8:566–572.
   PubMed Web of Science ®Google Scholar
• Gupta S, Yel L, Kim D, et al. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther 2003;2:711–719.
   PubMed Web of Science ®Google Scholar
• Yih LH, Hsu NC, Kuo HH, et al. Inhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxid. Toxicol Sci 2012;128:126–136.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Lin YP, Chow LP, et al. Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide -induced mitotically arrested cells. Proteomics 2011;11:4331–4345.
   PubMed Web of Science ®Google Scholar
• Wu YC, Yen WY, Lee TC, et al. Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxid-induced mitotic apoptosis. Toxicol Appl Pharmacol 2009;236:231–238.
   PubMed Web of Science ®Google Scholar
• Pelicano H, Carew JS, McQueen TJ, et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 2006;20:610–619.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345–3353.
   PubMed Web of Science ®Google Scholar
• Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001;97:264–269.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043–1052.
   PubMed Web of Science ®Google Scholar
• Figueiredo-Pereira ME, Chen WE, Li J, et al. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem 1996;271:16455–16459.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167–181.
   PubMed Web of Science ®Google Scholar
• Morceau F, Schnekenburger M, Blasius R, et al. Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Lett 2006;240:203–212.
   PubMed Web of Science ®Google Scholar
• Skotheim JM, Ditalia S, Siggia ED, et al. Positive feedback or G1 cyclins ensures coherent cell cycle entry. Nature 2008;454: 291–296.
   PubMed Web of Science ®Google Scholar
• Porosnicu M, Nimmanapalli R, Nguyen D, et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001;15:772–778.
   PubMed Web of Science ®Google Scholar
• Bae JY, Kim JW, Kim I. Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. Oncol Rep 2013;30:485–491.
   PubMed Web of Science ®Google Scholar
• Zhang HG, Wang J, Yang X, et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009–2015.
   PubMed Web of Science ®Google Scholar